ACM
Aisling Capital Management Portfolio holdings
AUM
$360M
This Quarter Return
+24.83%
1 Year Return
+114.67%
3 Year Return
+1,171.46%
5 Year Return
+892.24%
10 Year Return
–
AUM
$360M
AUM Growth
+$360M
(+25%)
Cap. Flow
+$4.98M
Cap. Flow
% of AUM
1.38%
Top 10 Holdings %
Top 10 Hldgs %
99.63%
Holding
13
New
–
Increased
2
Reduced
–
Closed
–
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$2.73M |
| 2 |
Biomea Fusion
BMEA
|
$2.25M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$9.89B
| $262M | 72.85% | 6,068,125 | – | – |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $58.2M | 16.18% | 615,352 | – | – |
|
|
3
Syndax Pharmaceuticals
SNDX
$1.41B
| $12.3M | 3.43% | 1,316,806 +291,806 | +28% | +$2.73M |
|
4
Monte Rosa Therapeutics
GLUE
$296M
| $6.64M | 1.85% | 1,472,331 | – | – |
|
|
BCAX
5
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $5.29M | 1.47% | 568,919 | – | – |
|
6
Nuvation Bio
NUVB
$1.02B
| $4.95M | 1.38% | 2,541,009 | – | – |
|
|
7
Biomea Fusion
BMEA
$116M
| $3.69M | 1.03% | 2,048,757 +1,250,000 | +156% | +$2.25M |
|
|
CMPS
8
Compass Pathways
CMPS
$424M
| $3.36M | 0.93% | 1,198,418 | – | – |
|
|
ELEV
9
DELISTED
Elevation Oncology
ELEV
| $1.04M | 0.29% | 2,834,910 | – | – |
|
10
CalciMedica
CALC
$37.7M
| $834K | 0.23% | 521,114 | – | – |
|
11
Aclaris Therapeutics
ACRS
$209M
| $617K | 0.17% | 434,455 | – | – |
|
12
Marker Therapeutics
MRKR
$12M
| $498K | 0.14% | 325,370 | – | – |
|
|
OKUR
13
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $212K | 0.06% | 88,607 | – | – |
|